{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:11:07Z","timestamp":1788887467920,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Topical Steroid Damaged\/Dependent Face (TSDF) is described as \u2018the semi-permanent or permanent damage to the skin of the face precipitated by the irrational, indiscriminate, unsupervised, or prolonged use of TCs resulting in a plethora of cutaneous signs and symptoms and psychological dependence on the drug\u2019. Its management is difficult due to the unavailability of a universally accepted treatment regimen, as well as a high rate of rebound after stopping therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To study the efficacy and safety of the application of 10% tranexamic acid solution in Topical Steroid Damaged\/Dependent Faces.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this non-randomised interventional study, 15 cases with TSDF were treated with topical 10% tranexamic acid solution applied once daily for 8 weeks and followed up every 4 weeks up to 12 weeks. Erythema, the hallmark of TSDF, was graded based on the Clinician\u2019s Erythema Assessment (CEA) scale, and improvement in this score was recorded at every follow-up visit along with clinical photographs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Erythema, photosensitivity and telangiectasia were present in all our subjects, followed by pigmentary abnormalities, acneiform eruptions, hypertrichosis and atrophy. Based on the reduction in CEA, we recorded a statistically significant improvement in erythema at week 4, and complete resolution of the same in 100% of our subjects by week 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Topical 10% tranexamic acid solution is a novel, promising, safe and efficacious modality in the treatment of TSDF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_121_24","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:01:05Z","timestamp":1779199265000},"page":"360-365","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Topical 10% Tranexamic Acid in Topical Steroid-Damaged Faces: A Non-Randomised Interventional Study"],"prefix":"10.4103","volume":"71","author":[{"given":"Pranami","family":"Kashyap","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and STD, North-Eastern Indira Gandhi Regional Institute of Health and Medical Science (NEIGRIHMS), Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Marak","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and STD, North-Eastern Indira Gandhi Regional Institute of Health and Medical Science (NEIGRIHMS), Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Verma","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and STD, North-Eastern Indira Gandhi Regional Institute of Health and Medical Science (NEIGRIHMS), Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Kumari","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and STD, North-Eastern Indira Gandhi Regional Institute of Health and Medical Science (NEIGRIHMS), Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0019-5154.182417","article-title":"Topical steroid damaged\/dependent face (TSDF): An entity of cutaneous pharmacodependence","volume":"61","author":"Lahiri","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-4362.1979.tb01905.x","article-title":"Steroid addiction","volume":"18","author":"Kligman","year":"1979","journal-title":"Int J Dermatol"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0019-5154.26949","article-title":"Abuse of topical steroid as cosmetic cream: A social background of steroid dermatitis","volume":"51","author":"Rathi","year":"2006","journal-title":"Indian J Dermatol"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40264-015-0287-7","article-title":"Topical corticosteroid-induced skin atrophy: A comprehensive review","volume":"38","author":"Barnes","year":"2015","journal-title":"Drug Saf"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/idoj.IDOJ_301_17","article-title":"Dermoscopy of topical steroid damaged\/dependent face","volume":"9","author":"Jakhar","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2019.12.067","article-title":"Topical 10% Tranexamic acid for erythematotelangiectatic steroid induced rosacea","volume":"86","author":"Jakhar","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","article-title":"Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial","volume":"78","author":"Draelos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.jaad.2019.09.074","article-title":"Topical 5% tranexamic acid for acne-related post inflammatory erythema","volume":"82","author":"Jakhar","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijdvl.IJDVL_801_16","article-title":"A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma","volume":"85","author":"Khurana","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/ijdd.ijdd_37_17","article-title":"Tranexamic acid in melasma: Why and how?","volume":"3","author":"Dashore","year":"2017","journal-title":"Indian J Drugs Dermatol"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.4103\/idoj.IDOJ_97_20","article-title":"Topical 10% tranexamic acid for recalcitrant topical steroid-dependent face","volume":"11","author":"Jakhar","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R13-20260908","first-page":"675","article-title":"Topical corticosteroids abuse: A clinical study of cutaneous adverse effects","volume":"62","author":"Meena","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/17469872.1.4.547","article-title":"The red skin syndromes: Corticosteroid addiction and withdrawal","volume":"1","author":"Rapaport","year":"2006","journal-title":"Expert Rev Dermatol"},{"key":"R15-20260908","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/ijd.IJD_218_17","article-title":"Topical steroid damaged\/dependent face (TSDF): A study from a tertiary care hospital in eastern India","volume":"63","author":"Pal","year":"2018","journal-title":"Indian J Dermatol"},{"key":"R16-20260908","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/0378-6323.77455","article-title":"Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients","volume":"77","author":"Saraswat","year":"2011","journal-title":"Indian J Dermatol Venereol Leprolo"},{"key":"R17-20260908","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/idoj.IDOJ_259_19","article-title":"Study of clinical profile of patients presenting with topical steroid-induced facial dermatosis to a tertiary care hospital","volume":"11","author":"Jain","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R18-20260908","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.18203\/2319-2003.ijbcp20202944","article-title":"Clinico-epidemiological study of topical steroid dependent face in a tertiary care hospital at Mysore","volume":"9","author":"Skandashree","year":"2020","journal-title":"Int JBasic Clin Pharmacol"},{"key":"R19-20260908","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20173926","article-title":"Topical steroid abuse on face: A prospective study from a tertiary care centre of north India","volume":"3","author":"Nyati","year":"2017","journal-title":"Int J Res Dermatol"},{"key":"R20-20260908","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7241\/ourd.20152.35","article-title":"Topical corticosteroids: Abuse and misuse","volume":"6","author":"Inakanti","year":"2015","journal-title":"Our Dermatol Online"},{"key":"R21-20260908","doi-asserted-by":"crossref","first-page":"226","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20232534","article-title":"Study of clinicodermoscopicfeatures of topical steroid damaged face patients","volume":"9","author":"Kushwah","year":"2023","journal-title":"Int J Res Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_121_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:02:25Z","timestamp":1788886945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_121_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_121_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"2024-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}